Position in BMY
as of Jun 30, 2026
· filed Jul 31, 2026
Position Value
$666,951
-$35,072 QoQ
Shares Held
11,575
0.0% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#1,388
of 2,506 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in BMY Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Cove Private Wealth, LLC holds $15,609,330 across 10 Drug Manufacturers - General names. BMY ranks #7 (4.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
17,139 | $4,352,791 | |
| 2 | ABBV |
AbbVie Inc.
|
12,350 | $3,107,754 | |
| 3 | PFE |
Pfizer Inc
|
84,332 | $2,030,714 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
14,803 | $1,870,211 | |
| 5 | MRK |
Merck & Co., Inc.
|
9,510 | $1,222,035 | |
| 6 | LLY |
ELI LILLY & Co
|
925 | $1,109,472 | |
| 7 | BMY |
Bristol Myers Squibb Co
This page
|
11,575 | $666,951 | |
| 8 | NVS |
Novartis AG
|
2,867 | $449,316 |
All Filings in BMY
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $666,951 | 11,575 | Shares | Sole | 2026-07-31 | |
| 2026-03-31 | $702,023 | 11,575 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $624,355 | 11,575 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $553,377 | 12,270 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $618,665 | 13,365 | Shares | Sole | 2025-07-16 | |
| 2025-03-31 | $691,931 | 11,345 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $508,757 | 8,995 | Shares | Sole | 2025-01-16 | |
| 2024-09-30 | $465,401 | 8,995 | Shares | Sole | 2024-10-25 | |
| 2024-06-30 | $422,360 | 10,170 | Shares | Sole | 2024-07-24 | |
| 2024-03-31 | $551,519 | 10,170 | Shares | Sole | 2024-05-01 | |
| 2023-12-31 | $521,822 | 10,170 | Shares | Sole | 2024-03-12 | |
| No filing history on record for this holder in this stock. | ||||||